Liabooks Home|PRISM News

#Samsung Biologics

Total 1 articles

Samsung Biologics Buys GSK's U.S. Facility for $280M in Major North American Push
EconomyEN
Samsung Biologics Buys GSK's U.S. Facility for $280M in Major North American Push

Samsung Biologics is acquiring a U.S. drug production facility from GSK for $280 million. The deal marks a significant expansion into the North American CDMO market, aiming to secure local production capacity.